Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
An annual tradition is a reflection on the key developments in the field over the past year. This year saw some major advances, with several of the biggest changes bubbling just below the surface and about to really break out in 2015. So without further adieu, here's my list.
For those who wish to access the pdf, it's here: Top 5 Highlights in Lung Cancer 2014
Agree? Disagree? What's highest on your wish list for 2015?
Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center explains how immune therapy works and how it might impact the future of lung cancer treatment.